Start Your Search
Poster Session (ID 8)
- Event: ACLC 2018
- Type: Poster Session
- Presentations: 2
- Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
P026 - Impact of Prior Cancer History on the Overall Survival of Younger Patients with Lung Cancer (ID 202)
00:00 - 00:00 | Author(s): H. Zhou
Patients with a history of prior cancer are frequently excluded from cancer trials. Previous studies indicated that prior cancer does not adversely impact clinical outcomes for lung cancer patients older than 65 years. However, whether these research results are applicable to lung cancer patients aged younger than 65 years old remains unknown.
We identified younger lung cancer patients (<65 years) diagnosed between 2004 and 2009 in the SEER database. Propensity score matching were performed to balance differences in baseline characteristics between groups. Kaplan-Meier method and Cox proportional hazards model were used to evaluate the impact of prior cancer on overall survival (OS).
Among 103,370 eligible lung cancer patients, 15.18% (15696) had a history of prior cancer. Lung (25.83%), breast (14.13%), and prostate (8.85%) were the most common prior cancer. Localized and regional stages were accounting for 61.56% of prior cancers. More than 67.98% of prior cancer were diagnosed within 5 years. The median times of diagnosis for prior cancers were 38 months. The Kaplan-Meier curve (Figure 1 A) show an adverse effect of prior cancer on OS, compared to patients without an prior cancer (p=0.029). In COX regression analysis, patients with prior cancer had the similar OS as that of patients without a prior cancer (hazard ratio = 1.01, 95% confidence interval= 0.99 to 1.04, p=0.324). Subgroup analyses stratified by timing of prior cancer displayed almost the same tendency (p>0.05) (Figure 1 B). Early stage patients with prior cancer had adverse survival curves (p<0.05). Advanced stage patients with prior cancer had non-inferior survival (p>0.05).
Prior cancer does not convey an adverse effect on clinical outcomes among advanced lung cancer patients age ? 65 years , regardless of timing of prior cancer. Broader inclusion trial criteria could be adopted in younger advanced lung cancer patients with a history of prior cancer.
P038 - Docosapentaenoic Acid and Lung Cancer Risk: A Mendelian Randomisation Study (ID 54)
00:00 - 00:00 | Author(s): H. Zhou
Docosahexaenoic acid and eicosapentaenoic acid have been reported to be associated with lung cancer risk; however, it remains unknown whether docosapentaenoic acid (DPA), another kind of n-3 PUFA, is related to lung cancer risk. The aim of this study is to investigate the causal effect of DPA on lung cancer with Mendelian randomization (MR) method.
With a two-sample MR approach, we analyzed the summary data from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE, 8,866 individuals of European ancestry) Consortium and International Lung Cancer Consortium (ILCCO, 11348 lung cancer cases and 15861 controls; European ancestry). Three single nucleotide polymorphisms (SNPs) that were genome-wide significant (p<5*10-8; linkage disequilibrium r2 < 0.1) for plasma DPA levels in CHARGE were explored for their associations with lung cancer risk in the ILCCO. Analysis for two different histologic subtypes of lung cancer (adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC)) was performed to investigate whether the effect of DPA is associated with the histology of lung cancer. To investigate whether lung cancer might be a causal factor for DPA, we performed an MR analysis in the opposite direction using 3 SNPs linked to lung cancer. Evidence of directional pleiotropy averaged across all variants was sought using MR